Gene expression in obese patients with non-alcoholic steatohepatitis;Expresión génica en pacientes obesos con enfermedad hepática por depósito de grasa

Revista Espanola de Enfermedades Digestivas

Volumn 100, Issue 4, 2008, Pages 212-218

  Cayon A ^a   Crespo, Javier ^a   Guerra, A R ^a   Pons Romero, F ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Morbid obesity; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; DEATH RECEPTOR 5; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 2; MESSENGER RNA; PROHIBITIN; PROTEIN BIGH3OBR; PROTEIN P55; PROTEIN TYROSINE RECEPTOR; REGULATOR PROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULOTROPIN;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; MICROARRAY ANALYSIS; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; CYTOKINES; FATTY LIVER; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; OBESITY, MORBID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 47049111917     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
2. Bacon BR, Farahvash MJ, Janney CG, Neusch-Wander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterol 1994; 107: 1103-9.
3. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 2003: 63: 2379-94.
4. Poves Prim I, Macías GJ, Cabrera Fraga M, Situ L, Ballesta López C. Calidad de vida en la obesidad mórbida. Rev Esp Enferm Dig 2005; 97: 187-95.
5. Day CP, James OFW. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114: 842-5.
6. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: A four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24: 99-106.
7. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 575-94.
8. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004; 37: 1499-507.
9. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 405-55.
10. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterol 2001; 120: 1183-92.
11. Solís Herruzo JA, García Ruiz I, Pérez Carreras M, Muñoz Yagüe MT. Enfermedad grasa del hígado no alcohólica. Desde la resistencia a la insulina a la disfunción mitocondrial. Rev Esp Enferm Dig 2006; 98: 844-74.
12. Romero-Gómez M. Hepatitis C y resistencia a la insulina: esteatosis, fibrosis y no respuesta. Rev Esp Enferm Dig 2006; 98: 605-15.
13. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
14. Pérez-Carreras M, del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1000.
15. Crespo J, Cayón A, Fernández-Gil P, Hernández Guerra M, Mayorga M, Domínguez-Díez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
16. Crespo J, Cayón A, Mayorga M, Domínguez-Díez A, Hernández-Guerra M, Fernández-Gil P, et al. Role of transforming growth factor beta (TGF-β) in hepatic fibrosis of non-alcoholic steatohepatitis patients. Madrid: EASL; 2002.
17. Kaser S, Moschen A, Cayón A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 2005; 54: 117-21.
18. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665-74.
19. Younossi ZM, Gorreta F, Ong JP, Schlauch K, Giacco LD, Elariny H, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 2005; 25: 760-71.
20. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
21. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3-16.
22. Chomczynski P, Sacchi V. Single step method of RNA isolation by acid guanidium thiocynate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
23. Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW, et al. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J 2000; 19 (11): 2444-51.
24. Kirchman PA, Miceli MV, West RL, Jiang JC, Kim S, Jazwinski SM. Prohibitins and Ras2 protein cooperate in the maintenance of mitochondrial function during yeast aging. Acta Biochim Pol 2003; 50: 1039-56.
25. Nijtmans LG, Artal SM, Grivell LA, Coates PJ. The mitochondrial PHB complex: Roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci 2002; 59: 143-55.
26. Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA, et al. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res 2001; 265: 262-73.
27. Santamaría E, Ávila MA, Latasa MU, Rubio A, Martín-Duce A, Lu SC, et al. Functional proteomics of nonalcoholic steatohepatitis: Mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003; 100: 3065-70.
28. Suh SK, Hood BL, Kim BJ, Conrads TP, Veenstra TD, Song BJ. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics 2004; 4: 3401-12.
29. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121-38.
30. Miyakawa K, Myint YY, Takahashi K. Effects of recombinant human macrophage colony-stimulating factor on proliferation, differentiation and survival of Kupffer cells in the liver of adult mice. Anal Quant Cytol Histol 1999; 21: 329-35.
31. Pinzani M, Abboud HE, Gesualdo L, Abboud SL. Regulation of macrophagecolony stimulating factor in liver fat-storing cells by peptide growth factors. Am J Physiol 1992; 262 (4 Pt 1): C876-81.
32. Itoh Y, Okanoue T, Ohnishi N, Nishioji K, Sakamoto D, Nagao Y, et al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver 1999; 19 (2): 97-103.
33. Itoh Y, Okanoue T, Enjyo F, Sakamoto S, Ohmoto Y, Nirai Y, et al. Serum levels of macrophage colony stimulating factor (M-CSF) in liver disease. J Hepatol 1994; 21 (4): 527-35.
34. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37 (1): 87-95.
35. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003; 17 (1): 94-6.
36. Anonni G, Weiner FR, Zern MA. Increased transforming growth factor beta 1 gene expression in human liver disease. J Hepatol 1992; 14: 259-64.
37. Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995; 21: 760-6.
38. Kinnman N, Andersson U, Hulterantz R. In situ expression of transforming growth factor beta 1-3, latent transforming growth factor beta binding protein and tumor necrosis factor alpha in liver tissue from patients with chronic hepatitis C. Scand J Gastroenterol 2000; 35: 1294-300.
39. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed family. Endocr Rev 1999; 20: 189-206.
40. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125-30.
41. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disease. J Invest Dermatol 1996; 106: 729-33.
42. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-61.
43. Paradis V, Dargere D, Vidaud M, De Gouville, Huet S, Martínez V, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30: 9688-976.
44. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hiperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
45. Saile Matthes N, Knittel T, Ramadori G. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology 1999; 30: 196-202.
46. Knittel T, Muller R, Saile B, Ramadori G. Effect of tumor necrosis factor alpha on proliferation, activation, and protein synthesis of rat hepatic stellate cells. J Hepatol 1997; 27: 1067-80.
47. Liu X, Wu H, Liu F, Huang M, Qiang O, Huang S. Effects of tumor necrosis factor alpha on the expression of connective tissue growth factor in hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2001; 9 (Sup. l): 15-7.
48. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: Regulation by TNF-α and TGF-β1. J Hepatol 1999; 30: 48-60.
49. Rosenbaum J, Blazejewski S, Preaux AM, Mallat A, Dhumeaux D, Mavier P. Fibroblast growth factor 2 and transforming growth factor beta 1 interactions in human liver myofibroblasts. Gastroenterology 1995; 109 (6): 1986-96.
50. Ankoma-Sey V, Matli M, Chang KB, Lalazar A, Donner DB, Wong L, et al. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 1998; 17 (1): 115-21.
51. Kimura K, Ando K, Ohnishi H, Ishikawa T, Kakumu S, Takemura M, et al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int Immunol 1999; 11 (9): 1491-500.
52. Castilla-Cortázar I, García M, Muguerza B, Quiroga J, Pérez R, Santidrián S, et al. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 1997; 113: 1682-91.
53. Shmueli E, Miell JP, Stewart M, Alberti KG, Record CO. High insulin-like growth factor binding protein 1 levels in cirrhosis: Link with insulin resistance. Hepatology 1996; 24: 127-33.
54. Shmueli E, Record CO, Alberti KG. Insulin independent glucose uptake in cirrhosis. Hepatology 1995; 21: 265-6.
55. Shmueli E, Stewart M, Alberti KG, Record CO. Growth hormone, insulin-like growth factor-1 and insulin resistance in cirrhosis. Hepatology 1994; 19: 322- 8.
56. Lee PD, Jensen MD, Divertie GD, Heiling VJ, Katz HH, Conover CA. Insulinlike growth factor-binding protein-1 response to insulin during suppression of endogenous insulin secretion. Metabolism 1993; 42: 409-14.
57. Wu JC, Daughaday WH, Lee SD, Hsiao TS, Chou CK, Lin HD, et al. Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988; 112: 589-94.
58. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244-51.